Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
Yun Liu,Narasimha M Beeraka,Junqi Liu,Kuo Chen,Bo Song,Zhang Song,Jianchao Luo,Yang Liu,Anping Zheng,Yanhui Cui,Yang Wang,Zhenhe Jia,Xiangyu Song,Xiaohong Wang,Hongqi Wang,Xuefeng Qi,Jinshan Ren,Liping Wu,Jixing Cai,Xainying Fang,Xin Wang,Mikhail Y Sinelnikov,Vladimir N Nikolenko,M V Greeshma,Ruitai Fan,Liu,Y.,Beeraka,N. M.,Liu,J.,Chen,K.,Song,B.,Song,Z.,Luo,J.,Liu,Y.,Zheng,A.,Cui,Y.,Wang,Y.,Jia,Z.,Song,X.,Wang,X.,Wang,H.,Qi,X.,Ren,J.,Wu,L.,Cai,J.,Fang,X.,Wang,X.,Sinelnikov,M. Y.,Nikolenko,V. N.,Greeshma,M. V.,Fan,R.
DOI: https://doi.org/10.1136/bmjopen-2021-055273
IF: 3.006
2022-04-26
BMJ Open
Abstract:Introduction Oesophageal squamous cell carcinoma (OSCC) is one of the most commonly occurring devastating tumours worldwide, including in China. To date, the standard care of patients with stage IV OSCC is systemic chemotherapy and palliative care, which results in poor prognosis. However, no consensus has been established regarding the role of radiotherapy in targeting the primary tumour in patients with stage IVa OSCC. Thus, the aim of this study is to assess the effectiveness of primary radiotherapy combined with S-1 and nedaplatin (NPD) chemotherapy in the patients with stage IV OSCC. Methods and analysis The study is a multicentre, open-label, randomised controlled trial. A total of 180 eligible patients with stage IV OSCC will be randomised into a study group (90 patients) and a control group (90 patients). Patients in the study group will receive radiotherapy to the primary tumour at a dose of 50.4 Gy combined with 4–6 cycles of S-1 and NPD chemotherapy. In the control group, patients will only receive 4–6 cycles of S-1 and NPD chemotherapy. The primary and secondary outcomes will be measured. The differences between the two groups will be statistically analysed with regard to overall survival, the progression-free survival and safety. All outcomes will be ascertained before treatment, after treatment and after the follow-up period. The results of this study will provide evidence on the role of radiotherapy in patients with stage IV OSCC in China, which will show new options for patients with advanced oesophageal cancer. Ethics and dissemination This study was approved by the Institutional Ethics Committee of The First Hospital Affiliated of Zhengzhou University (approval number: SS-2018–04). Trial registration The trial has been registered at the Chinese Clinical Trial Registry (ChiCTR1800015765) on 1 November 2018; retrospectively registered, http://www.chictr.org.cn/index.aspx.
medicine, general & internal